カテゴリー： IMARC, 世界, 医療/バイオ

インソムニアの世界市場2022-2028：産業動向、シェア、規模、成長、機会・予測

◆英語タイトル：Insomnia Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

IMARCが発行した調査報告書（IMARC23FE0042）◆商品コード：IMARC23FE0042
◆発行会社（リサーチ会社）：IMARC
◆発行日：2023年2月1日
◆ページ数：144
◆レポート形式：英語 / PDF
◆納品方法：Eメール
◆調査対象地域：グローバル
◆産業分野：医薬品
◆販売価格オプション（消費税別）
Single UserUSD2,999 ⇒換算￥455,848見積依頼/購入/質問フォーム
Five UserUSD3,999 ⇒換算￥607,848見積依頼/購入/質問フォーム
EnterprisewideUSD4,999 ⇒換算￥759,848見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

IMARC社発行の当調査資料によると、2022年51億ドルであった世界のインソムニア市場規模が2028年には61億ドルに達し、予測期間中、年平均3％成長すると予測されています。当書は、インソムニアの世界市場について総合的に調査・分析されたレポートです。序論、範囲・調査手法、エグゼクティブサマリー、イントロダクション、治療タイプ別（非薬物療法、薬物療法）分析、薬物クラス別（抗うつ剤、メラトニン拮抗薬、ベンゾジアゼピン系、非ベンゾジアゼピン系、その他）分析、流通チャネル別（病院薬局、小売薬局、ドラッグストア、オンライン薬局）分析、地域別（北米、アジア太平洋、ヨーロッパ、中南米、中東/アフリカ）分析、SWOT分析、バリューチェーン分析、ファイブフォース分析、価格分析、競争状況などの項目がまとめられています。なお、当書に掲載されている企業情報には、Astellas Pharma Inc.、Aurobindo Pharma Limited、Biocodex、Eisai Co. Ltd.,Mallinckrodt Pharmaceuticals、Merck & Co. Inc.、Neurim Pharmaceuticals Inc.、Pfizer Inc.、Sanofi S.A.、Sumitomo Dainippon Pharma Co. Ltd. (Sumitomo Chemical Co. Ltd.)、Takeda Pharmaceutical Company Limited、Vanda Pharmaceuticals Inc.などが含まれています。
・序論
・範囲・調査手法
・エグゼクティブサマリー
・イントロダクション

・世界のインソムニア市場規模：治療タイプ別
- 非薬物療法の市場規模
- 薬物療法の市場規模

・世界のインソムニア市場規模：薬物クラス別
- 抗うつ剤の市場規模
- メラトニン拮抗薬の市場規模
- ベンゾジアゼピン系インソムニアの市場規模
- 非ベンゾジアゼピン系インソムニアの市場規模
- その他薬物クラスの市場規模

・世界のインソムニア市場規模：流通チャネル別
- 病院薬局の市場規模
- 小売薬局の市場規模
- ドラッグストアの市場規模
- オンライン薬局の市場規模

・世界のインソムニア市場規模：地域別
- 北米のインソムニア市場規模
- アジア太平洋のインソムニア市場規模
- ヨーロッパのインソムニア市場規模
- 中南米のインソムニア市場規模
- 中東/アフリカのインソムニア市場規模

・SWOT分析
・バリューチェーン分析
・ファイブフォース分析
・価格分析
・競争状況
・主要企業情報

The global insomnia market size reached US$ 5.1 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 6.1 Billion by 2028, exhibiting a growth rate (CAGR) of 3% during 2023-2028.

Insomnia is a sleep disorder that can lower energy levels and affect the mood, health, work performance, and overall life quality of an individual. Its common causes include stress, long travels, hectic work schedules, poor sleep habits, binge eating, and excessive consumption of nicotine, caffeine, and alcohol. It can also be associated with mental health disorders, such as post-traumatic stress, and the use of drugs like antidepressants for asthma or blood pressure and over-the-counter (OTC) for pain relief, allergy, and cold. Its treatment options, such as cognitive-behavioral therapy (CBT), OTC sleep aids, and prescription medications like Eszopiclone and Ramelteon, are currently available worldwide.

Insomnia Market Trends:
The coronavirus disease (COVID-19) pandemic generated unprecedented changes in lives, including social isolation and innumerable work challenges and family obligations. This acts as a major stressful event that impacted the sleep patterns of millions and strengthened the market growth. Moreover, medical conditions, such as chronic pain, cancer, diabetes, heart disease, asthma, gastroesophageal reflux disease (GERD), overactive thyroid, Parkinson’s disease, and Alzheimer’s disease, are usually linked with insomnia. Hence, the increasing number of individuals suffering from these ailments is driving the demand for insomnia medications. Apart from this, hormonal shifts during the menstrual cycle and menopause can lead to the risk of developing insomnia, which is contributing to the market growth. In addition, as changes in sleep patterns, activity, and health and the rising use of prescription drugs can increase the chance of insomnia among older people, the growing geriatric population globally is catalyzing the demand for insomnia medical treatment. Furthermore, increasing investments in testing new treatments, interventions, and tests to prevent, detect, treat, and manage insomnia are anticipated to drive the market.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global insomnia market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on therapy type, drug class and distribution channel.

Breakup by Therapy Type:

Non-Pharmacological Therapy
Hypnotherapy
Cognitive Behavioral Therapy
Medical Devices
Others
Pharmacological Therapy
Prescription Sleep Aids
Over-The-Counter Sleep Aids

Breakup by Drug Class:

Antidepressants
Melatonin Antagonist
Benzodiazepines
Nonbenzodiazepines
Orexin Antagonist
Others

Breakup by Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Astellas Pharma Inc., Aurobindo Pharma Limited, Biocodex, Eisai Co. Ltd., Mallinckrodt Pharmaceuticals, Merck & Co. Inc., Neurim Pharmaceuticals Inc., Pfizer Inc., Sanofi S.A., Sumitomo Dainippon Pharma Co. Ltd. (Sumitomo Chemical Co. Ltd.), Takeda Pharmaceutical Company Limited and Vanda Pharmaceuticals Inc.

Key Questions Answered in This Report:
How has the global insomnia market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global insomnia market?
What are the key regional markets?
What is the breakup of the market based on the therapy type?
What is the breakup of the market based on the drug class?
What is the breakup of the market based on the distribution channel?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global insomnia market and who are the key players?
What is the degree of competition in the industry?

❖ レポートの目次 ❖

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Insomnia Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Therapy Type
6.1 Non-Pharmacological Therapy
6.1.1 Market Trends
6.1.2 Key Segments
6.1.2.1 Hypnotherapy
6.1.2.2 Cognitive Behavioral Therapy
6.1.2.3 Medical Devices
6.1.2.4 Others
6.1.3 Market Forecast
6.2 Pharmacological Therapy
6.2.1 Market Trends
6.2.2 Key Segments
6.2.2.1 Prescription Sleep Aids
6.2.2.2 Over-The-Counter Sleep Aids
6.2.3 Market Forecast
7 Market Breakup by Drug Class
7.1 Antidepressants
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Melatonin Antagonist
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Benzodiazepines
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Nonbenzodiazepines
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Orexin Antagonist
7.5.1 Market Trends
7.5.2 Market Forecast
7.6 Others
7.6.1 Market Trends
7.6.2 Market Forecast
8 Market Breakup by Distribution Channel
8.1 Hospital Pharmacies
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Retail Pharmacies
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Drug Stores
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Online Pharmacies
8.4.1 Market Trends
8.4.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Astellas Pharma Inc.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 Aurobindo Pharma Limited
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.3 Biocodex
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.4 Eisai Co. Ltd.
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.4.4 SWOT Analysis
14.3.5 Mallinckrodt Pharmaceuticals
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.6 Merck & Co. Inc.
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.6.4 SWOT Analysis
14.3.7 Neurim Pharmaceuticals Inc.
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.8 Pfizer Inc.
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.8.4 SWOT Analysis
14.3.9 Sanofi S.A.
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.9.3 Financials
14.3.9.4 SWOT Analysis
14.3.10 Sumitomo Dainippon Pharma Co. Ltd. (Sumitomo Chemical Co. Ltd.)
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.10.3 Financials
14.3.10.4 SWOT Analysis
14.3.11 Takeda Pharmaceutical Company Limited
14.3.11.1 Company Overview
14.3.11.2 Product Portfolio
14.3.11.3 Financials
14.3.11.4 SWOT Analysis
14.3.12 Vanda Pharmaceuticals Inc.
14.3.12.1 Company Overview
14.3.12.2 Product Portfolio
14.3.12.3 Financials



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ インソムニアの世界市場2022-2028：産業動向、シェア、規模、成長、機会・予測(Insomnia Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • リンパ腫治療の世界市場2023～2028：産業動向、シェア、規模、成長、機会・予測
  • 非黒色腫皮膚がん治療の世界市場2023～2028：産業動向、シェア、規模、成長、機会・予測
  • 放射線腫瘍学の世界市場2023～2028：産業動向、シェア、規模、成長、機会・予測
  • 前立腺がん治療の世界市場2022-2028：産業動向、シェア、規模、成長、機会・予測
  • 血液悪性腫瘍の世界市場2023～2028：産業動向、シェア、規模、成長、機会・予測

    • ◆H&Iグローバルリサーチのお客様（例）◆